Pharm
Propofol
search
Propofol
, Diprivan
See Also
Procedural Sedation and Analgesia
(
PSAA
)
Rapid Sequence Intubation
Mechanism
Sedative Hypnotic
Potentiates
Gamma-Aminobutyric Acid
receptors
No
Analgesic
effect
Administer concurrent
Analgesic
s (typically given 20-30 minutes prior to Propofol start)
Drug Abuse
potential (especially among anesthesiologists, nurse anesthetists, emergency medicine staff, dentists)
Increases
Dopamine
levels which may reinforce addiction
Increases
Serotonin
levels which may be
Hallucinogen
ic
References
Majoewsky (2012) EM:RAP 12(1): 3
Precautions
See
Procedural Sedation and Analgesia
(
PSAA
)
Propofol has no
Analgesic
effect, and therefore
Opioid Analgesic
s are often used before Propofol
Propofol (esp. with concurrent
Opioid
s) increases the risk of cardiopulmonary depression (
Hypoxia
,
Hypotension
)
Close monitoring is critical (second provider skilled in airway management is preferred)
Consider pre-procedure crystalloid bolus of 500 ml (or 10-20 ml/kg)
Consider oxygen via nasal canula at 2 L/min
Suction, Bag-valve mask,
Nasopharyngeal Airway
, and intubation equipment should be ready for use
Consider
Capnography
Pharmacokinetics
Rapid onset and short
Half-Life
Lipid
-soluble and crosses blood-brain barrier
Onset: 30-45 seconds (<1 minute)
Duration: 6 minutes on average (5 to 15 minutes, prolonged with repeated dosing)
Lipid
emulsion bottle is at risk of
Bacteria
l contamination and growth once accessed
Discard any open bottles after 12 hours
Preparation
See
Procedural Sedation
Second provider skilled in airway management (preferred)
Preventive measures
Pre-procedure crystalloid bolus of 500 ml (or 10-20 ml/kg)
Oxygen via nasal canula at 2 L/min
Opioid Analgesic
s given at least 20 minutes before procedure
Monitoring Equipment
Pulse Oximetry
(
Oxygen Saturation
and
Heart Rate
)
Blood Pressure
cuff, manual or automatic cycled every few minutes
Consider
Capnography
Emergency Equipment
Wall Suction (typically with yanker catheter tip)
Bag-valve mask
Nasopharyngeal Airway
Intubation equipment (see
Advanced Airway
)
Dosing
Adults
Conscious Sedation
(not FDA approved)
Adult (preferred procedural
Sedative
)
Initial: 0.5 to 1 mg/kg IV over 20-30 seconds (typically given as smaller increments)
Obese patients: Consider 0.7 to 0.8 mg/kg for starting dose
Thin young patients: Consider 1.5 mg/kg for starting dose (risk of respiratory depression)
Frail elderly patients: Consider 20-30 mg IV for starting dose
Next: 0.25 to 0.5 mg/kg IV every 1 to 3 minutes
Decrease dose in older patients (cummulative required total dose decreases with age)
Age 18-40 years old: 2 mg/kg total dose
Age 41-64 years old: 1.7 mg/kg total dose
Age >64 years old: 1.2 mg/kg total dose
Patanwala (2013) J Emerg Med 44(4): 823-8 +PMID:23333181 [PubMed]
Typically no respiratory depression at 1 mg/kg dose
Amnesia
occurs at this dose
Perform painful procedures immediately following infusion
Amnestic effect wears off prior to sedation
Propofol Infusion for
Procedural Sedation
Infusion: 100 to 150 mcg/kg/min (6 to 9 mg/kg/h)
Intubation Sedation (not FDA approved)
Dose 2 to 2.5 mg/kg IV over 20 to 30 seconds
Ventilator
sedation in ICU
Infusion: 5-50 mcg/kg/min
Anesthesia
Age under 55 years old
Titration: 40 mg IV every 10 seconds until induction achieved
Typical cummulative total dose: 2 to 2.5 mg/kg
Maintenance infusion: 100-200 mcg/kg/min
Age 55 years old or older
Decrease dose from that list above for younger patients
Dosing
Children
Avoid for prolonged ICU use
See
Propofol Infusion Syndrome
Conscious Sedation
(not FDA approved)
Initial: 1 mg/kg IV (up to 40 mg) over 20-30 seconds (typically given as smaller increments)
Dose per kilogram typically higher in children than adults for adequate sedation
Age <3 years: 2 mg/kg
Older children and teens: 1.5 mg/kg
May repeat 0.5 to 1 mg/kg IV (up to 20 mg maximum) every 1 to 3 minutes as needed
Propofol Infusion for
Procedural Sedation
Infusion: 100 to 250 mcg/kg/min (6 to 15 mg/kg/h)
Anesthesia
(age 3 years and older)
Typical cummulative total dose: 2.5 to 3.5 mg/kg over 20-30 seconds
Maintenance infusion: 125-300 mcg/kg/min
Indications
Procedural Sedation and Analgesia
(
PSAA
)
Indicated for
ASA Physical Status
Score 2 (non-hypotensive, stable)
Rapid Sequence Intubation
Other agents (e.g.
Etomidate
,
Ketamine
) are preferred for emergency department induction (
Hypotension
risk)
Contraindications
Relative
See
Procedural Sedation and Analgesia
(
PSAA
)
Age <6 months or weight <5 kg
Age >75 years old
ASA Physical Status
Class 3 and above
Soy allergy (soybean allergy) is no longer considered a contraindication
Egg allergy (egg Lecithin allergy) is no longer considered a contraindication
Adverse Effects
Propofol Infusion Syndrome
Seen with prolonged use (not associated with short-term
Procedural Sedation and Analgesia
)
Hypertriglyceridemia
(with prolonged infusion)
Propofol is a lipid-based infusion that contains 1 kcal/ml
Risk of
Acute Pancreatitis
Devlin (2005) Pharmacotherapy 25(10):1348-52 +PMID:16185179 [PubMed]
Cardiopulmonary adverse effects (reduced by administering with lower dose and slower titration)
Respiratory depression
More common in older adults
Close monitoring by a second provider skilled in airway management is preferred
Consider oxygen via nasal canula at 2 L/min
Suction, Bag-valve mask,
Nasopharyngeal Airway
, and intubation equipment should be ready for use
Consider
Capnography
Transient
Hypotension
and myocardial depression
Systolic
Blood Pressure
drops 10-18 mmHg, Diastolic
Blood Pressure
drops 10-16 mmHg
Consider pre-procedure crystalloid bolus of 500 ml (or 10-20 ml/kg)
Increase time (>20 minutes) between IV
Opioid
s and Propofol
Consider alternative
Sedative
s (e.g.
Etomidate
or
Ketamine
) in hypotensive patients
Phenylephrine
may be used to counter the hypotensive effects of Propofol
Overdose
No antidote
Manage with
ABC Management
and supportive care
Safety
Avoid in
Lactation
However some references recommend no delay in
Lactation
Pregnancy category B
However, minimal data available
Not
Teratogen
ic based on limited data
Resources
Propofol (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3105799-a4b6-f3f4-e6e2-b2b29bbdb538
References
Acker, Koval and Leeper (2017) Crit Dec Emerg Med 31(4): 3-13
Miller (2019) Ann Emerg Med 73(5): 470-80 [PubMed]
Type your search phrase here